As such, the inhibitor of apoptosis (IAP) protein survivin is an attractive target for anticancer immunotherapy, since it is a near universally over-expressed tumor antigen in human cancers, whereas its expression is low or undetectable in most differentiated adult tissues (14). Here, BIRC5 is linked to cancer.